- Newborns Living Near Trees Tend to Be Healthier. New Data Suggests It’s Not Because Healthier People Reside Near Parks.
- What's the Benefit of Opening for Taylor Swift?
- Taste Research Suggests Pearl Millet Could be a Healthy, Sustainable, Gluten-free Wheat Alternative in the U.S.
- New Data Finds Health Care Organizations May Not Be Doing Enough to Connect Patients with Housing Services When They’re Needed Most.
德雷塞尔大学开发的伤口愈合技术离成为医疗护理人员的工具又近了一步。 北弗吉尼亚再生医学设备公司Eqalix最近获得了DrexelJDB电子研究人员发明的蛋白质纳米纤维支架技术的专利保护。
U.S. Patent No. 8,790,921, entitled “Alimentary Protein-Based Scaffolds (APS) for Wound Healing, Regenerative Medicine and Drug Discovery” is an important step for Eqalix, the company that licensed the technology from Drexel, as it seeks to bring it to market as a product called OmegaSkin™.
“This patent covering Eqalix’s OmegaSkin™ wound dressing is an important milestone in our effort to commercialize this technology and recognition of the highly innovative approach to replace human and animal sources for advanced wound dressings with an easier to harvest and process and less costly plant source,” said Thomas Seoh, Eqalix president and chief executive officer.
OmegaSkin™ is made from natural soy proteins in contrast to current wound dressing options made from human sources such as neonatal foreskin or cadaver skin, or animal sources such as cows, horses or pigs. It was developed by researchers in Drexel’s School of Biomedical Engineering, Science and Health Systems with funding from the Coulter-Drexel Translational Research Partnership Program.
“This patent issuance, covering a unique and highly original invention that was made with partial financial support of the Coulter-Drexel Translational Research Partnership Program funded by the Walter H. Coulter Foundation, adds to Drexel’s growing leadership in the generation of important biomedical technologies,” said Kenneth Barbee, PhD, interim director designate of the School of Biomedical Engineering, Science and Health Systems.
In May, data were published in the medical journal, Wound Medicine, showing pre-clinically relevant healing in wounds treated with OmegaSkin™ compared to those treated with a control dressing in a pig model of wound healing. Eqalix plans to file appropriate product applications with the Food and Drug Administration and other regulatory bodies to obtain marketing approval for the management of a range of acute and chronic wounds.
About Eqalix
Eqalix is a regenerative medicine company based in Reston, Virginia, USA that is developing a novel plant protein-based tissue scaffold product candidate intended to treat acute and chronic wounds, a small diameter vascular graft product candidate that may promote re-endothelialization, and other product candidates for tissue repair and regeneration. For more information, visit www.eqalix.com.
About The Coulter-Drexel Translational Research Partnership Program
The Coulter-Drexel Translational Research Partnership Program invests in translational research aimed at advancing biomedical technologies toward commercialization under the guidance of the Coulter Program Director’s office and a team of advisors consisting of investors and representatives of industry and regional economic development agencies. The program was established and endowed by the Wallace H. Coulter Foundation with $10 million, which was matched by Drexel University, for a $20 million fund to support the program in perpetuity.
Disclaimer:
联合国